Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

ts are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether experimental pain models of pain, including the capsaicin model, are accurate in predicting efficacy of novel analgesics in early clinical trials, whether the results of any Phase II trial or other study of NGX426 will be consistent with the results of the study reported in this press release, whether TorreyPines will be able to complete any potential strategic or financing transaction on terms acceptable to TorreyPines' stockholders, how the volatile economic environment will affect TorreyPines' efforts to complete a strategic or financing transaction, whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical tri
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015  The Paul G. Allen Family Foundation announced ... to six groups of researchers with projects at the ... neuroscience: growing mature human brain cells in the laboratory. ... million over three years.  "This new ... especially significant because the field of neuronal maturation is ...
(Date:4/30/2015)... 2015 Available in select spas ... , Fleur’s introduces CC CRÈME ... benefits of makeup, skin care and solar protection ... is designed with specific complexion-correcting pigments to instantly ... and a healthy glow. Far more than a ...
(Date:4/29/2015)... According to a new market ... (Portable & Non-Portable), Component (Accelerometer, Proximity Probe, & ... & Mining, & Others), & Geography - Global ... to reach $1,453.76 Million by 2020, at a ... tables and 92 figures spread through 205 pages ...
(Date:4/29/2015)... AlloSource ®, one of the ... and soft-tissue allografts for use in surgical procedures ... the launch of AlloSkin™ AC, an acellular dermal ... (CMS) also moved AlloSkin™ RT, a meshed human ... category for reimbursement. "AlloSource is committed ...
Breaking Biology Technology:The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4AlloSource Announces New Possibilities In Wound Care 2
... EMERYVILLE, Calif., Jan. 3, 2012  Bionovo, Inc. (NASDAQ: ... discovery and development of safe and effective treatments for ... entered into a $5 million securities purchase agreement with ... Socius Capital Group, LLC. (Logo: ...
... Jan. 3, 2012 Dear NeoStem Shareholders, ... back at 2011 - a transformative year for NeoStem (NYSE Amex: ... term catalysts that we expect to move the company forward in ... Progenitor Cell Therapy, LLC ("PCT") and Amorcyte, LLC ("Amorcyte"). , ...
... NEW YORK, Jan. 3, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0203539/Cytogenetics---technologiesmarkets-and-companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics ... cytogenetics in a broader sense rather than ...
Cached Biology Technology:Bionovo Announces $5 Million Financing 2Bionovo Announces $5 Million Financing 3Bionovo Announces $5 Million Financing 4NeoStem's CEO Letter to Shareholders 2NeoStem's CEO Letter to Shareholders 3NeoStem's CEO Letter to Shareholders 4Cytogenetics - Technologies, Markets and Companies 2Cytogenetics - Technologies, Markets and Companies 3Cytogenetics - Technologies, Markets and Companies 4Cytogenetics - Technologies, Markets and Companies 5Cytogenetics - Technologies, Markets and Companies 6Cytogenetics - Technologies, Markets and Companies 7Cytogenetics - Technologies, Markets and Companies 8Cytogenetics - Technologies, Markets and Companies 9Cytogenetics - Technologies, Markets and Companies 10Cytogenetics - Technologies, Markets and Companies 11
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Lolle and colleagues from Purdue University published a paper in ... do not obey the laws of Mendelian inheritance (the idea ... found that these plants were demonstrating genetic traits from older ... of how genes are passed on. At the ...
... Bethesda, MD The Federation of American Societies ... registration for the Science Research Conference (SRC): Mechanism ... 2013 FASEB Science Research Conference on Mechanism and ... 23 in Saxton Rivers, VT. The "Vermont Transcription ...
... mid-nineteenth century, maps have helped elucidate the deadly mysteries ... global mapping of infectious diseases is considerably unreliable and ... outbreaks, according to a new systematic mapping review of ... the 355 infectious diseases assessed in the review, 174 ...
Cached Biology News:Defying the laws of Mendelian inheritance 2Avoiding a cartography catastrophe 2
Request Info...
...
... to Atrophin 1 ( Abpromise for ... Synthetic peptide conjugated to KLH derived ... of Human Atrophin 1.(Note: the amino acid ... .) Entrez GeneID: ...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
Biology Products: